Bristol-Myers shares fall after failed AstraZeneca drug trial

(Reuters) - Bristol-Myers Squibb Co shares fell 5 percent on Thursday as investors bet that a failed cancer drug trial at AstraZeneca has negative implications for Bristol-Myers' similar immunotherapy treatment regimen.